Versameb raises CHF 6.4 million in Seed C round and strengthens the team

Basel (ots) - Versameb AG, a Swiss biopharmaceutical company,
announced today the successful closing of a CHF 6.4 million Seed C
financing round, bringing the total capital raised to date to CHF
11.8 million. Versameb is focusing on the discovery and development
of innovative, next-generation RNA-based drugs.

The proceeds of this financing round will be used to expand the
company's proprietary technology platform, VERSagile, in multiple
indications and advance the lead program towards clinical studies.
The VERSagile technology platform enables efficient development of
functional mRNA molecules for customized protein expression and
modification in various therapeutic indications.

"We are very pleased and grateful to see the interest of new
investors, as well as the strong confidence shown by our existing
shareholders," said Prof. Dr. Friedrich Metzger, CEO of Versameb.

Team strengthened with new Chairman of the Board and Chief
Business Officer

At the 2019 Annual Shareholder Meeting, Dr. Reinhard Ambros was
elected as a Member of the Board of Directors and was subsequently
appointed Chairman succeeding Roger Meier. Reinhard has built the
Novartis Venture Fund to a leading corporate biotech venture fund and
has held various leadership positions in venture capital, corporate
strategy, BD&L and pharmaceutical drug development. His exceptional
professional experience adds relevant expertise and insight to
Versameb's Board of Directors.

Reinhard Ambros commented: "I was attracted to join Versameb
because I see a great potential in its unique mRNA technology
platform and the ambitious goals to develop next-generation RNA
therapies. I look forward to serve as Chairman of the Board and work
with this outstanding team to play a part in Versameb's future
development."

In addition, Versameb has recently appointed Dr. Isabel Ferreira
as Chief Business Officer. In her role, Isabel Ferreira will be
responsible for leading the company's global partnering and corporate
development strategy and execution. Isabel Ferreira served most
recently in Roche Partnering as Director Global Business Development,
led strategic projects and cross-functional teams to deal closure.
Prior to joining Roche, she acted as Senior Director Business
Development in a Dutch Biotech company that was listed on NASDAQ in a
successful IPO in 2013 and was acquired by BioMarin early 2015.

"I am excited to welcome Reinhard and Isabel to our team. Their
extensive experience and successful track record deepen our business
expertise as we take the company to the next level and execute on our
growth strategy," said Friedrich Metzger, CEO of Versameb. "On behalf
of the Board, I also thank Roger for his guidance and leadership over
the past two years, helping us to successfully grow the company. I am
very pleased that he will continue to support us on the Board of
Directors."

About Versameb AG

Versameb AG is a preclinical-stage biopharmaceutical company
located in Basel, Switzerland managed by an experienced scientific
and business pharmaceutical industry team.

The company's focus is the development of novel RNA-based
therapeutics. Versameb's proprietary VERSagile technology platform
enables efficient development of functional mRNA molecules for
customized protein expression and modification in multiple disease
areas with high unmet medical need.

For more information, please visit www.versameb.com.

Pressekontakt:
Contact for Media Enquiries
Tatsuo Satoh
Operations Director

Versameb AG
Hochbergerstrasse 60C
CH-4058 Basel
+41 61 638 23 56
+41 78 819 17 44
tatsuo.satoh@versameb.com

Original-Content von: Versameb AG, übermittelt durch news aktuell